Treace Medical Concepts, Inc. Overview
Pro stress-test →Treace Medical Concepts is a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities. Q1 2026 revenue was $47.2 million, down 10% year-over-year, with a net loss of $18.0 million.
Strategic Profile
Pro stress-test →The company is growing year-over-year case volumes while taking market share, though revenue dollars declined due to product and price mix shifts. In 2026, Treace plans to commercialize Lapiplasty Lightning, a next-generation platform designed to reduce surgical steps and support greater accuracy of 3D bunion correction. Management expects full-year 2026 revenue of $202–$212 million with approximately 50% reduction in cash usage versus 2025.
Competitive Landscape
Pro stress-test →Treace competes in surgical bunion treatment, a specialized orthopedic segment. Primary competitors include established orthopedic device companies offering bunion surgical solutions, including Zimmer Biomet (ZMRX), Stryker (SYK), and Smith & Nephew (SNN), which have broader musculoskeletal portfolios, as well as specialized bunion-focused competitors like Acumed (part of Thoratec/Arthrex ecosystem). Treace's differentiation centers on minimally invasive 3D correction technology.
Industry Context
Treace Medical Concepts, Inc. operates in Minimally invasive orthopedic surgical devices.
Key facts
Founded: N/A · Headquarters: Ponte Vedra Beach, US · Employees: N/A · Revenue: $212.7M (FY 2025); Q1 2026: $47.2M · Market cap: N/A